Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset-Reference-Cited by-同舟云学术

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Published:2018-12-01 Issue:1 Volume:49 Page:29-36
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Ohe Yuichiro¹,Imamura Fumio²,Nogami Naoyuki³,Okamoto Isamu⁴,Kurata Takayasu⁵,Kato Terufumi⁶,Sugawara Shunichi⁷,Ramalingam Suresh S⁸,Uchida Hirohiko⁹,Hodge Rachel¹⁰,Vowler Sarah L¹⁰,Walding Andrew¹⁰,Nakagawa Kazuhiko¹¹

Affiliation:

1. Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

2. Department of Thoracic Oncology, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan

3. Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Minamiumemoto-machi, Matsuyama, Japan

4. Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan

5. Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan

6. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanazawa-ku, Yokohama, Japan

7. Department of Pulmonary Medicine, Sendai Kousei Hospital, Aoba-ku, Sendai, Japan

8. Winship Cancer Institute, Emory University, Atlanta, GA, USA

9. Research and Development, AstraZeneca K.K., Grand Front Osaka Tower B, Kita-ku, Osaka, Japan

10. AstraZeneca, Cambridge, da Vinci Building, Melbourn Science Park, Melbourn, Cambridgeshire, UK

11. Department of Medical Oncology, Kindai University Hospital, Ohno-higashi, Osaka, Japan

Funder

AstraZeneca

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/49/1/29/27565507/hyy179.pdf

Reference24 articles.

1. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update;Hanna;J Clin Oncol,2017

2. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

3. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival;Lee;J Natl Cancer Inst,2017

4. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation;Oxnard;Clin Cancer Res,2011

5. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study;Respiratory Investigation;2024-03

2. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005);Lung;2024-01-24

3. The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases;Frontiers in Oncology;2024-01-19

4. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset;Cancer Research and Treatment;2024-01-15

5. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis;Clinical Lung Cancer;2024-01